TrialSite has emphasized the interest, and frankly necessity, of biopharmaceutical companies to monetize this pandemic has become palpable in the pervasive influence of the pharmaceutical lobby permeating throughout society. Pfizer is on a trajectory to generate $33 billion in one year not necessarily counting full exploitation of the broad interpretation of booster needs across the U.S. and beyond. To put things in perspective, blockbuster drug status means sales over $1 billion or up per annum. Eli Lilly one of the more prominent American pharmaceutical companies targets nearly $27 billion in sales involving many products. Now imagine Pfizer now generates $33 billion for one product—during a pandemic.
That’s partially the name of the COVID-19 game, shareholder wealth as the pressure has mounted to drive booster programs across the country. In an unprecedented alignment of interests, a Democrat Party lead mandate all but ensures not only a massive marketing and sales channel but also thanks to the enactment of the PREP Act during the pandemic the companies such as Pfizer have absolutely no liability unless a plaintiff can prove criminal behavior.
Note: If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).